CN114990163A - Lentiviral vector for stem cell gene modification and construction method and application thereof - Google Patents
Lentiviral vector for stem cell gene modification and construction method and application thereof Download PDFInfo
- Publication number
- CN114990163A CN114990163A CN202210342741.2A CN202210342741A CN114990163A CN 114990163 A CN114990163 A CN 114990163A CN 202210342741 A CN202210342741 A CN 202210342741A CN 114990163 A CN114990163 A CN 114990163A
- Authority
- CN
- China
- Prior art keywords
- vector
- lentiviral vector
- rfp
- pgk
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 title claims abstract description 63
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 25
- 238000012239 gene modification Methods 0.000 title claims abstract description 15
- 238000010276 construction Methods 0.000 title abstract description 9
- 230000005017 genetic modification Effects 0.000 claims abstract 3
- 235000013617 genetically modified food Nutrition 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 44
- 238000005520 cutting process Methods 0.000 claims description 26
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 241000713666 Lentivirus Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 108090000174 Interleukin-10 Proteins 0.000 claims description 14
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 102000003814 Interleukin-10 Human genes 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 230000002519 immonomodulatory effect Effects 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 108010002352 Interleukin-1 Proteins 0.000 claims description 3
- 108090000978 Interleukin-4 Proteins 0.000 claims description 3
- 108090001005 Interleukin-6 Proteins 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 230000014509 gene expression Effects 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000007365 immunoregulation Effects 0.000 abstract description 3
- 108700008625 Reporter Genes Proteins 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 24
- 239000013612 plasmid Substances 0.000 description 24
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 13
- 241000700605 Viruses Species 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 10
- 238000001976 enzyme digestion Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 6
- 239000012154 double-distilled water Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 210000003954 umbilical cord Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 239000012124 Opti-MEM Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000004957 immunoregulator effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 239000013600 plasmid vector Substances 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000009168 stem cell therapy Methods 0.000 description 3
- 238000009580 stem-cell therapy Methods 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 239000006067 antibiotic powder Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000002660 stem cell treatment Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 1
- 239000012880 LB liquid culture medium Substances 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000003144 genetic modification method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 102000052620 human IL10 Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 210000002444 unipotent stem cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a lentiviral vector for stem cell gene modification and a construction method and application thereof. The vector can be used for genetic modification of stem cells and endows the stem cells with stronger immunoregulation capability. Meanwhile, the expression of the reporter gene RFP is beneficial to the pharmacokinetics research before clinic, and lays the theoretical foundation of the early stage for the development of clinical tests.
Description
Technical Field
The invention relates to a lentivirus vector and preparation and application thereof, belonging to the technical field of biology.
Background
Stem cells are a class of cells that have not been fully differentiated, have self-renewal, high proliferation and differentiation potential. Stem cells can be classified into three types, i.e., pluripotent stem cells, multipotent stem cells and unipotent stem cells, according to the size of differentiation potential; stem cells can be classified into two types, embryonic stem cells and adult stem cells, depending on the developmental stage. Stem cell therapy refers to the process of applying stem cells from human autologous or allogeneic sources to transfuse (implant) into a human body after in vitro operation and acting on disease treatment. The stem cells have great development potential and clinical application value in the fields of disease treatment, tissue repair, anti-aging, beauty treatment and the like, and become one of the important directions in the field of life science in recent years. Although the stem cells have a wide clinical application prospect, the clinical application of the stem cells also faces some challenges, for example, how to effectively improve the treatment effect of the stem cell treatment is the key point for further popularization and application of the stem cell treatment.
It is a common technical method at present to enhance the expression of specific proteins in cells by using a genetic modification method so as to directionally endow a certain cell with specific functions. And has been widely used in the field of disease treatment, for example, chimeric antigen receptor T cells, which utilize recombinant lentiviruses to transduce foreign gene expression, thereby conferring T cells with the ability to recognize specific tumor antigens, thereby targeted killing of tumor cells. Therefore, the importance of gene modification and the safety of gene modification have been widely recognized by the scientific community, and the relationship between human health, environment, agricultural development, economy and politics has been intensively studied and gradually advanced into the lives of people. Stem cells have immunomodulatory effects and stem cell therapy has important research value in a number of tissue inflammatory diseases, such as osteoarthritis. However, it is one of the directions of research on stem cell therapy to safely and effectively genetically modify stem cells to improve their therapeutic effects on osteoarthritis.
Disclosure of Invention
The invention discloses a lentiviral vector pLL3.7-EF1a-MCS-PGK-RFP for stem cell gene modification, a construction method thereof and application thereof in preparation of osteoarthritis drugs. The invention also establishes a method for detecting the virus titer by the flow cytometry, and provides a detection standard for clinical application. The invention provides a lentiviral vector pLL3.7-EF1a-MCS-PGK-RFP for stem cell gene modification, the nucleotide sequence and map of which are shown in figure 1:
the invention also discloses a preparation method of the lentiviral vector pLL3.7-EF1a-MCS-PGK-RFP, which comprises the following steps:
s1: synthesis of EF1-MCS sequences
The sequence of the pLL3.7 vector (the sequence of the pLL.7 vector is shown as SEQ ID NO. 1) is analyzed by using SnapGene software to obtain a corresponding map (shown in figure 1), and a single enzyme cutting site XbaI (located at 7170bp) and a single enzyme cutting site Pci I (1390bp) are found to be capable of cutting a CMV + EGHFP element (a sequence with the length of 1867bp is cut out together) on the initial vector, and the size of the vector after cutting is 5780 bp. The synthesized EF1a-MCS-PGK-RFP sequence is added with Xba I or Pci I sequence at two ends. The total length of the synthetic gene is 1646bp (shown in SEQ ID NO. 2). The sequence of the synthesized EF1a-MCS-PGK-RFP gene containing XbaI and PciI enzyme cutting sites is shown as SEQ ID NO. 3.
S2:
The pLL3.7 vector (purchased from Shanghai Yang Sheng) and the EF1a-MCS-PGK-RFP sequence containing the restriction enzyme sites Xba I and PciI are subjected to double enzyme digestion by restriction enzymes Xba I and PciI, and the target products after enzyme digestion are respectively recovered.
The invention also discloses a using method of the lentivirus vector pLL3.7-EF1a-MCS-PGK-RFP, which comprises the following steps:
step 1: cloning a target gene into a pLL3.7-EF1a-MCS-PGK-RFP vector to obtain a recombinant lentivirus vector;
step 2: co-transfecting the recombinant lentiviral vector obtained in the step 1, psPAX2 and pMD2.0G into a host cell;
and step 3: culturing a host cell, wherein the host cell is a 293T cell;
and 4, step 4: and separating to obtain the recombinant lentivirus.
The invention also discloses a recombinant lentiviral vector, which is prepared by the following method: the neutralizing antibody sequences of the immunomodulatory cytokine genes or anti-inflammatory cytokines are cloned into the polyclonal site of a vector such as pLenti-EF 1-MCS-PGK-RFP. Wherein the immunoregulatory cytokine gene is selected from the group consisting of human TGF-beta, IL-10, IL-4, and the like, or any combination thereof. Neutralizing antibodies against inflammatory cytokines include anti-human IL-6, TNF-a, IL-1, and the like.
The invention has the following beneficial effects: the lentiviral vector for stem cell gene modification can be used for stem cell gene modification and endows stem cells with stronger immunoregulatory capacity. Meanwhile, the expression report gene RFP is helpful for the pharmacokinetics research before clinic, and lays the theoretical foundation of the early stage for the development of clinical tests.
Drawings
The accompanying drawings, which are included to provide a further understanding of the invention and are incorporated in and constitute a part of this specification, illustrate embodiments of the invention and together with the description serve to explain the principles of the invention and not to limit the invention. In the drawings:
FIG. 1 is a map of the pLL3.7 plasmid vector;
FIG. 2 shows a diagram of double-restriction electrophoresis of pLL3.7-EF1a-MCS-PGK-RFP recombinant plasmid;
FIG. 3 pLL3.7-EF1a-MCS-PGK-RFP plasmid map;
FIG. 4 double digestion of pLL3.7-EF1a-IL-10-PGK-RFP recombinant lentiviral vector plasmid;
FIG. 5 pLL3.7-EF1-IL-10-PGK-RFP recombinant lentiviral vector plasmid map;
FIG. 6 fluorescent microscope observation of cells expressing red fluorescence;
FIG. 7 ELISA detects IL-10 secretion levels.
Detailed Description
The preferred embodiments of the present invention will be described in conjunction with the accompanying drawings, and it will be understood that they are described herein for the purpose of illustration and explanation and not limitation.
Examples
The preparation method of the lentivirus vector pLL3.7-EF1a-MCS-PGK-RFP comprises the following steps:
step 1: synthesis of EF1-MCS sequence (Suzhou Jinwei Zhi Biotechnology Co., Ltd.)
The sequence of the pLL3.7 vector (pLL.7 vector sequence is as follows) is analyzed by using SnapGene software to obtain a corresponding map (as shown in figure 1), and a single enzyme cutting site XbaI (located at 7170bp) and a single enzyme cutting site Pci I (1390bp) are found to be capable of cutting off a CMV + EGHFP element (a sequence with the length of 1867bp is cut off together) on the initial vector, and the size of the vector after cutting off is 5780 bp. The synthesized EF1a-MCS-PGK-RFP sequence is added with Xba I or Pci I sequence at two ends. The total length of the synthetic gene is 1646bp (the sequence is shown below).
The sequence of the pLL3.7 plasmid vector is shown in SEQ ID NO. 1.
The EF1a-MCS-PGK-RFP gene sequence containing XbaI and PciI enzyme cutting sites and formed by Jinzhi Biotechnology Limited, Suzhou is shown as SEQ ID NO. 3.
And 2, step:
the pLL3.7 vector (purchased from Shanghai Kangshihibul) and the EF1a-MCS-PGK-RFP sequence containing the enzyme cutting sites Xba I and PciI are subjected to double enzyme cutting by using restriction enzymes Xba I and Pci I, and target products after enzyme cutting are respectively recovered;
the specific method comprises the following steps:
1) enzyme digestion
pLL3.7 plasmid or EF1a-MCS-PGK-RFP gene 1ug, 1. mu.L restriction enzyme Xba I (NEB, R0145S) and 1. mu.L restriction enzyme Pci I (NEB, R0655S), 5ul were addedBuffer (NEB), and finally double distilled water was added to make the whole reaction volume 50. mu.L. The sample is placed at 37 ℃ for reaction for 1 hour;
2) linearized plasmid recovery
Required reagent
1 × TAE: 4.84g Tris (sollabio, # T8060-100g), 0.744g Na2EDTA.2H2O (Shanghai test, #10009717), 1.142mL glacial acetic acid (national drug, #10000218) were fully dissolved in appropriate amount of ddH2O, and the volume was determined to 1L for use.
Agarose (Biowest, BY-R0100)
Agarose gel recovery kit: common agarose gel DNA recovery kit (Tiangen, # DP209-02)
DNA loading: 6x DNA loading (gold overall, # GH101)
Experimental procedure
A. 1% agarose gel preparation
Weighing 0.5g of agarose, adding 50mL of 1 XTAE solution, uniformly mixing, boiling in a microwave oven for 2min, and adding into a gel tank for condensation;
B. agarose gel electrophoresis
Adding DNA loading to 1x of linearized plasmid and target fragment samples, adding into sample wells, and performing 150V electrophoresis for 15 min;
C. linearized plasmid and target band cutting gel
Cutting the agarose gel containing the target band under an ultraviolet gel cutting instrument and transferring the agarose gel into a new 1.5mL centrifuge tube;
D. destination strip recovery
The target fragment was recovered according to the procedure of the agarose gel recovery kit, and stored at-20 ℃ after the concentration was determined.
3) Connection of
Required reagent
Connecting the kit: minerva Super Fusion Cloning Kit (Suzhou Yuheng, # M2026-50T)
Experimental procedure
A. Reaction system
The following ligation reaction system was prepared:
*: adding the target gene segment recovered in the step 2) and the linearized vector into a reaction system according to a molar ratio of 2: 1.
B. Connection of
Mixing, and reacting at 37 deg.C for 30min
C. Storage of
After the reaction is finished, the ligation product containing the recombinant lentivirus plasmid pLL3.7-EF1a-MCS-PGK-RFP is obtained and is used immediately or stored at-20 ℃ for later use.
3) Transformation of
Required reagent
DH5 alpha competent cell (Kangshenghe, # KTSM101L)
LB liquid medium: 10G tryptone (Sigma-Aldrich, # T9410-250G), 5G yeast extract (Sigma-Aldrich, # T9410-250G), 10G NaCl (Hu test, #10019308) were added to ddH 2 Adjusting pH to 7.0 after O is dissolved, fixing volume to 1L, sterilizing at 121 deg.C under high pressure for 15min, and cooling to room temperature
LB solid medium: 10G tryptone (Sigma-Aldrich, # T9410-250G), 5G yeast extract (Sigma-Aldrich, # T9410-250G), 10G NaCl (Hu test, #10019308), adjusting pH to 7.0, adding 10G agar powder (avadin, # A109143-5kg), making a volume of 1L, autoclaving at 121 deg.C for 15min, and cooling to room temperature
Antibiotics: weighing 1g of corresponding antibiotic powder (sigma), dissolving in 20mL of double distilled water, sterilizing at 0.22 μm, filtering, washing hair, sterilizing, packaging, and storing at-20 deg.C
Experimental procedure
a. Taking a piece of DH5 alpha competence (100 mu L) to be placed on ice for unfreezing, sucking a proper amount of the ligation product obtained in the step 2) after the competence cells are unfrozen, adding the ligation product into the competence cells in the molten state, slightly blowing and beating for several times, uniformly mixing, and placing on ice for 20 min;
b. after the ice bath is finished, placing the mixture in a water bath kettle, thermally shocking the mixture for 90s at 42 ℃, and immediately placing the mixture on ice for 2 min;
c. adding 500 μ L of LB liquid culture medium without antibody into the mixture, resuscitating at 37 deg.C and 200rpm for 1 h;
d. sucking a proper amount of recovered bacteria liquid and coating the bacteria liquid on an LB solid culture medium containing 100 mu g/mL of corresponding antibiotics;
e.37 ℃ in an incubator, inverting the culture overnight to show that a monoclonal colony appears on an LB solid culture medium;
4) plasmid extraction
Required reagent
LB liquid medium: 10G tryptone (Sigma-Aldrich, # T9410-250G), 5G yeast extract (Sigma-Aldrich, #70161-500G), 10G NaCl (Shanghai test, #10019308) were dissolved in ddH2O, adjusted to pH 7.0, adjusted to 1L, autoclaved at 121 ℃ for 15min, and cooled to room temperature
Plasmid mini-extraction kit: omega plasmid petite kit (Omega, # D6943-01-100T)
Antibiotics: 1g of the corresponding antibiotic powder (sigma) was weighed and dissolved well in 20mL ddH 2 O, 0.22 mu m sterilizing, filtering, washing hair, sterilizing, subpackaging and storing at-20 ℃.
Experimental procedure
a) Picking a monoclonal grown in the LB solid medium in the step 3), adding 5mL of LB liquid medium containing 100 mu g/mL of corresponding antibiotics, and culturing overnight (12-16h) at 37 ℃ by a bacterial culture shaker at 200 rpm; (ii) a
b) Centrifuging 1.5-5 ml of bacterial liquid at room temperature of 10000 Xg for 1min
c) The supernatant was removed, 250. mu.l of solution I (containing RNase A) was added, and the cells were shaken by a vortex shaker until they were completely suspended.
d) Adding 250 mu l of solution II, and gently inverting the centrifuge tube for 4-6 times to obtain a clear lysate. Incubation for 2min at room temperature, vigorous mixing will shear the chromosomal DNA, reducing plasmid purity. (storage solution II should screw bottle cap)
e) Add 350. mu.l of solution III, mix gently by inversion several times until white flocculent precipitate appears, centrifuge at room temperature 10000 Xg for 10min.
f) The supernatant was aspirated with special care and transferred to a clean adsorption column equipped with 2ml centrifuge tubes. It is ensured that there are no aspiration deposits and cell debris. Centrifuging at room temperature 10000 Xg for 1min until the lysate completely passes through the absorption column
g) Discarding the filtrate, adding 500. mu.l Buffer HB, centrifuging at 10000 Xg for 1min, cleaning the absorption column, removing residual protein to ensure the purity of DNA.
h) If the following steps have low requirements on plasmid purity, such as enzyme digestion and other screening methods, the step can be omitted
i) Discarding the filtrate, washing the absorption column with 750. mu.l Wash Buffer diluted with 100% ethanol, centrifuging at 10000 Xg for 1min to note: the Wash Buffer concentrate must be diluted with pure ethanol before use, as indicated by the fact that if the label is frozen, it must be brought to room temperature before use.
j) This step is optional: then 750 mul Wash Buffer was added to clean the absorption column
k) The column must be centrifuged at 10000 Xg for 1min to ensure that the ethanol is removed, which can affect the next steps.
l) the column is placed in a clean 1.5ml centrifuge tube and 50-100. mu.l (depending on the desired final concentration) of sterile deionized water or TE buffer is added to the filter and centrifuged at 10000 Xg for 5 min.
m) measuring the concentration, and storing in a refrigerator at the temperature of 20 ℃ below zero for later use.
5) Enzyme digestion verification
Taking 1 μ g of the pLL3.7-EF1a-MCS-PGK-RFP plasmid recombinant plasmid extracted in the step 4), adding 1 μ L of restriction enzyme Pci I (NEB, R0655S) and 1 μ L of restriction enzyme XbaI (NEB, R0145S), and 5 μ LBuffer (NEB), and finally double distilled water was added to make the whole reaction volume 50. mu.L. The sample was left to react at 37 ℃ for 1 hour. Subsequently, the band of interest was ligated as determined by 1% agarose gel electrophoresis, which showed that a band of about 1800bp was cut. The double digestion results show that the pLL3.7-EF1a-MCS-PGK-RFP recombinant lentiviral vector plasmid is successfully constructed (as shown in FIG. 2).
The sequencing result and the EF1a-MCS-PGK-RFP synthesized sequence Blast are completely correct. Thus, the Pre-Lenti-EF1-MCS vector is successfully constructed. The full-length sequence of pLL3.7-EF1a-MCS-PGK-RFP is shown in SEQ ID NO.2, the vector map is shown in figure 3, and the length is as follows: 7420 bp.
The full-length sequence of Lenti-EF1a-MCS-PGK-RFP is shown in SEQ ID NO. 3.
The invention also discloses a using method of the lentivirus vector pLL3.7-EF1a-MCS-PGK-RFP, which comprises the following steps:
step 1: cloning a target gene into a pLL3.7-EF1a-MCS-PGK-RFP vector to obtain a recombinant lentivirus vector;
step 2: co-transfecting the recombinant lentiviral vector obtained in the step 1, psPAX2 and pMD2.0G into a host cell;
and 3, step 3: culturing a host cell, wherein the host cell is a 293T cell;
and 4, step 4: and separating to obtain the recombinant lentivirus.
The invention also discloses a recombinant lentiviral vector, which is prepared by the following method: the neutralizing antibody sequence of the immunomodulatory cytokine gene or anti-inflammatory cytokine is cloned into the polyclonal site of a vector such as pLenti-EF 1-MCS-PGK-RFP. Wherein the immunoregulatory cytokine gene is selected from the group consisting of human TGF-beta, IL-10, IL-4, and the like, or any combination thereof. Neutralizing antibodies against inflammatory cytokines include anti-human IL-6, TNF-a, IL-1, and the like.
Construction of expression human IL-10 Lentiviral vector pLL3.7-EF1-IL-10-PGK-RFP
IL-10 Gene Synthesis
1) Obtaining a CDS sequence of IL-10(Homo sapiens) from NCBI, analyzing an IL-10 gene sequence by using SnapGene software, and finding that single enzyme cutting sites EcoRI (a recognition sequence GAATTC) and BamHI (a recognition sequence GGATCC) are suitable for gene cloning and can be matched with a multiple cloning site of a pLL3.7-EF1-MCS-PGK-RFP vector; designing an IL-10 gene sequence containing an enzyme cutting site and a Kzake sequence as follows, and sending the gene sequence to Suzhou Jinwei Zhi Biotech limited for gene synthesis;
the gene sequence of IL-10 containing enzyme cutting site and Klake sequence is shown in SEQ ID NO. 4.
2.2 enzyme digestion
Double-enzyme cutting pLL3.7-EF1-MCS-PGK-RFP carrier and the IL-10 gene containing enzyme cutting sites BamH I and EcoR I by using restriction endonucleases BamH I and EcoR I, respectively recovering the target products after enzyme cutting; the enzyme digestion reaction system and the reaction conditions are constructed as the pLL3.7-EF1-MCS-PGK-RFP vector.
2.3 the product after digestion was recovered and the same procedure as that for the construction of pLL3.7-EF1-MCS-PGK-RFP vector was carried out using the Biomiga gel recovery kit (cat # DC-3511-01).
2.4 ligation, the procedure was identical to that of the construction of pLL3.7-EF1-MCS-PGK-RFP vector.
2.5 transformation, plating, and constructing the pLL3.7-EF1-MCS-PGK-RFP vector as before.
2.6 selecting clone, shaking bacteria, and constructing the vector by the same operation as the pLL3.7-EF1-MCS-PGK-RFP vector.
2.7 plasmid extraction, the procedure was the same as that of the pLL3.7-EF1-MCS-PGK-RFP vector construction, using the endotoxin-free plasmid extraction kit from Biomiga (cat # PD 1220-02).
2.8 enzyme digestion identification
Extraction step 2.7 extraction of recombinant plasmid 1. mu.g, adding 1. mu.L of restriction enzyme BamH I (NEB, R0136S) and 1. mu.L of restriction enzyme EcoR I (NEB, R0101S), 5. mu.LBuffer (NEB), and finally double distilled water was added to make the whole reaction volume 50. mu.L. The sample was left to react at 37 ℃ for 1 hour. Subsequent identification by 1% agarose gel electrophoresis revealed that the band of interest was ligated by cutting an approximately 543bp band. The double digestion result shows that the pLL3.7-EF1a-MCS-PGK-RFP recombinant lentiviral vector plasmid is successfully constructed (as shown in FIG. 4). For further confirmation, sequencing verification was performed and the sequencing results were aligned with the IL-10 gene and were completely correct. Thus, the IL-10 lentiviral vector pLL3.7-EF1-IL-10-PGK-RFP was obtained (vector map is shown in FIG. 5).
1:pLL3.7-EF1-IL-10-PGK-RFP
2: the pLL3.7-EF1-IL-10-PGK-RFP plasmid is subjected to double enzyme digestion by BamH I and EcoR I
III, pLL3.7-EF1-IL-10-PGK-RFP lentivirus package
3.1 Lentiviral packaging follows conventional methods, roughly as follows:
day 1 (afternoon): cell seeding
293T cells at 5X10 5 The density of individual cells/well was seeded in 6-well culture plates containing 2mL of lentivirus packaging medium. Cells were incubated overnight at 37 ℃ under 5% CO2 to ensure that cell densities reached 60-70% confluence during transfection.
Day 2 (morning): transfection
All plasmids were diluted to 1ug/ul with Opti-MEM;
1) tube A: 250ul of serum-free Opti-MEM medium diluted 7ul of Lipofectamine 3000 was vortexed for 10 s.
2) And a tube B: dilution of 4ug of plasmid pLL3.7-EF1-IL-10-PGK-RFP in 250ul serum-free Opti-MEM medium: 2ul, psPAX 2: 1.2ul, pMD2G:0.8ul) and 6ul of P3000 reagent were vortexed for 10 s.
3) Preparation of liposome-DNA complexes: transfer the tube contents to tube B and mix well and incubate for 10min at room temperature.
Prior to addition of the complexes, 1mL of medium was removed from each well to give a total volume of 1mL per well.
4) 500uL of liposome-DNA complex was added to each well, and the liquid was carefully added against the walls of the wells to avoid damaging the cells. The plate was gently agitated to distribute it evenly.
5) The plates were incubated at 37 ℃ with 5% CO2 for 8 hours.
6) After 8 hours of transfection, the plate medium in each well was replaced. The medium containing the liposome-DNA complexes was carefully aspirated from each well and the aspirated medium was treated with 10% bleaching solution before disposal. Replace with 2mL of pre-warmed lentiviral packaging medium.
7) The plates were returned to the incubator and incubated overnight at 37 ℃ under 5% CO 2.
Day 3: collecting the first batch of viruses
1) 48 hours after transfection, 2mL of cell supernatant (containing packaged recombinant lentivirus lenti-IL-10-RFP) was collected from each well, packed into 15mL conical tubes and stored at 4 ℃.
2) The collected medium was replaced with 2mL of pre-warmed lentiviral packaging medium.
3) The plates were incubated overnight at 37 ℃ with 5% CO 2.
Day 4: collecting a second batch of viruses
1) About 72 hours after transfection, 2mL of cell supernatant was collected from each well and mixed with the first collected supernatant to make the total volume of collected supernatant 4 mL.
2) Cell debris was removed by centrifugation at 2,000rpm for 10 minutes at room temperature. The supernatant was collected and transferred, and the cell pellet was discarded.
3) And (3) virus concentration: the collected supernatant was transferred to a sterile centrifuge tube according to a Lenti-X Concentrator: the supernatant was added to a Lenti-X Concentrator at a ratio of 1:3 and incubated overnight at 4 ℃.
5) Centrifuge at 1500g for 60min at 4 ℃ and discard the supernatant.
6) Adding DMEM basic culture medium to resuspend virus precipitate, subpackaging at 50 ul/tube, preserving at-80 ℃ in a refrigerator for standby, and limiting freeze-thaw times of the subpackaged virus so as to maintain virus titer.
3.2. And (4) determining the virus titer.
a. 293T cells according to 2X10 5 A 24-hole plate is paved on each hole; b. adding 293T cells according to three gradient virus concentrated solutions of 0.01ul, 0.1ul and 1 ul; c. detecting the RFP positive cell proportion by flow cytometry after 48 hours; d. calculate Titer Titer ═ according to the formula (2X 10) 5 x RFP positivity rate)/volume of added virus x1000 TU/ml.
Fourth, infection of mesenchymal Stem cells
Material
Human umbilical cord mesenchymal stem cells (Saiko biology, Cat number HUXUC)
Human umbilical cord mesenchymal stem cell complete medium (Youkang biology, cat # NC0103)
4.1 recovery and culture of human umbilical mesenchymal stem cells
a) A37 ℃ water bath was prepared.
b) Human umbilical cord mesenchymal stem cell complete medium was prepared and incubated to 37 ℃.
c) 9mL of human umbilical cord mesenchymal stem cell complete medium was added to a 15mL centrifuge tube.
d) The cryopreserved human umbilical cord mesenchymal stem cells are taken out of the liquid nitrogen tank and immediately placed into a refrigerator at the temperature of minus 80 ℃ (the aim is to slightly volatilize the liquid nitrogen entering the cryopreserved pipe).
e) Standing at-80 deg.C for 2-3min, taking out the frozen cells, quickly placing the frozen tube into 37 deg.C warm water, and quickly shaking to melt the contents in the tube as soon as possible. Carefully observing, and taking out the frozen tube after the contents of the frozen tube are completely melted.
f) The outer wall of the freezing storage pipe orifice is disinfected by 70% -75% alcohol.
g) The cryopreservation tube was opened in a clean bench and the cell cryopreservation suspension was transferred with a pipette into a 15mL centrifuge tube containing 9mL complete medium. During this process, it is desirable to avoid the generation of bubbles as much as possible.
h) To reduce cell loss, 1mL of complete medium was added to the vial, gently pipetted, and the 1mL of cell suspension was aspirated into the centrifuge tube using a pipette, and the cells in the centrifuge tube were gently pipetted and gently and pipetted into the tube.
i) The cell suspension was centrifuged for 5min at 250g (corresponding to 1134rpm for Eppendorf 5810R centrifuge). The supernatant was removed as much as possible and 1-2mL of complete medium (preheated to 37 ℃) was added to the cell pellet and gently pipetted evenly.
j) The cells were all inoculated into 1T 25 flask or culture vessel of equivalent bottom area, and sufficient complete medium was added. The cell culture vessel was gently shaken to evenly distribute the cells.
k) Culturing in an incubator at 37 deg.C and 5% CO2 with saturated humidity.
l) the next day after recovery, the recovered cells were replaced with fresh human umbilical mesenchymal stem cell complete medium (pre-warmed to 37 ℃).
m), cells were replaced with fresh complete medium every two days until the cells reached 80% confluence.
4.2 infection of human umbilical cord blood mesenchymal Stem cells by recombinant lentiviruses
a) The day before the experiment, the mesenchymal stem cells with the confluence degree reaching 80 percent in the step 1m) are treated according to the specification of 1x10 5 Inoculating into 6-well plate containing mesenchymal stem cell complete culture medium;
b) the cells reached 70-90% full, and the recombinant lentivirus obtained in step three was added in an amount of MOI ═ 5 (meaning viral particle number: mesenchymal stem cell number is 5:1), the mesenchymal stem cells are infected, polybrene is added during infection to enable the final concentration to reach 6 mug/mL, and the control hole is not infected with virus and is not added with polybrene;
c) after 72h infection, the expression of RFP was observed by fluorescence microscopy, and the level of IL-10 secretion was measured by collecting cell culture supernatants. The results showed that almost all cells expressed RFP fluorescence (fig. 6), and the level of IL-10 secretion was extremely significant compared to the control group (fig. 7).
The above results fully show that successfully constructing plasmid vector for expressing immunoregulation can be used for gene modification of stem cells and endow stem cells with stronger immunoregulation capability. Meanwhile, the expression of the reporter gene RFP is beneficial to the preclinical pharmacokinetic research and lays the early theoretical foundation for the development of clinical tests.
Finally, it should be noted that: although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art will understand that various changes, modifications and substitutions can be made without departing from the spirit and scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Sequence listing
<110> Mediterranean gorges (Fujian) cell Biotechnology Ltd
<120> lentiviral vector for stem cell gene modification, and construction method and application thereof
<141> 2022-03-31
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 7647
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gcattagtta ttaatagtaa tcaattacgg ggtcattagt tcatagccca tatatggagt 60
tccgcgttac ataacttacg gtaaatggcc cgcctggctg accgcccaac gacccccgcc 120
cattgacgtc aataatgacg tatgttccca tagtaacgcc aatagggact ttccattgac 180
gtcaatgggt ggagtattta cggtaaactg cccacttggc agtacatcaa gtgtatcata 240
tgccaagtac gccccctatt gacgtcaatg acggtaaatg gcccgcctgg cattatgccc 300
agtacatgac cttatgggac tttcctactt ggcagtacat ctacgtatta gtcatcgcta 360
ttaccatggt gatgcggttt tggcagtaca tcaatgggcg tggatagcgg tttgactcac 420
ggggatttcc aagtctccac cccattgacg tcaatgggag tttgttttgg caccaaaatc 480
aacgggactt tccaaaatgt cgtaacaact ccgccccatt gacgcaaatg ggcggtaggc 540
gtgtacggtg ggaggtctat ataagcagag ctggtttagt gaaccgtcag atccgctagc 600
gctaccggtc gccaccatgg tgagcaaggg cgaggagctg ttcaccgggg tggtgcccat 660
cctggtcgag ctggacggcg acgtaaacgg ccacaagttc agcgtgtccg gcgagggcga 720
gggcgatgcc acctacggca agctgaccct gaagttcatc tgcaccaccg gcaagctgcc 780
cgtgccctgg cccaccctcg tgaccaccct gacctacggc gtgcagtgct tcagccgcta 840
ccccgaccac atgaagcagc acgacttctt caagtccgcc atgcccgaag gctacgtcca 900
ggagcgcacc atcttcttca aggacgacgg caactacaag acccgcgccg aggtgaagtt 960
cgagggcgac accctggtga accgcatcga gctgaagggc atcgacttca aggaggacgg 1020
caacatcctg gggcacaagc tggagtacaa ctacaacagc cacaacgtct atatcatggc 1080
cgacaagcag aagaacggca tcaaggtgaa cttcaagatc cgccacaaca tcgaggacgg 1140
cagcgtgcag ctcgccgacc actaccagca gaacaccccc atcggcgacg gccccgtgct 1200
gctgcccgac aaccactacc tgagcaccca gtccgccctg agcaaagacc ccaacgagaa 1260
gcgcgatcac atggtcctgc tggagttcgt gaccgccgcc gggatcactc tcggcatgga 1320
cgagctgtac aagtaggaat tcgtcgaggg acctaataac ttcgtatagc atacattata 1380
cgaagttata catgtttaag ggttccggtt ccactaggta caattcgata tcaagcttat 1440
cgataatcaa cctctggatt acaaaatttg tgaaagattg actggtattc ttaactatgt 1500
tgctcctttt acgctatgtg gatacgctgc tttaatgcct ttgtatcatg ctattgcttc 1560
ccgtatggct ttcattttct cctccttgta taaatcctgg ttgctgtctc tttatgagga 1620
gttgtggccc gttgtcaggc aacgtggcgt ggtgtgcact gtgtttgctg acgcaacccc 1680
cactggttgg ggcattgcca ccacctgtca gctcctttcc gggactttcg ctttccccct 1740
ccctattgcc acggcggaac tcatcgccgc ctgccttgcc cgctgctgga caggggctcg 1800
gctgttgggc actgacaatt ccgtggtgtt gtcggggaaa tcatcgtcct ttccttggct 1860
gctcgcctgt gttgccacct ggattctgcg cgggacgtcc ttctgctacg tcccttcggc 1920
cctcaatcca gcggaccttc cttcccgcgg cctgctgccg gctctgcggc ctcttccgcg 1980
tcttcgcctt cgccctcaga cgagtcggat ctccctttgg gccgcctccc cgcatcgata 2040
ccgtcgacct cgatcgagac ctagaaaaac atggagcaat cacaagtagc aatacagcag 2100
ctaccaatgc tgattgtgcc tggctagaag cacaagagga ggaggaggtg ggttttccag 2160
tcacacctca ggtaccttta agaccaatga cttacaaggc agctgtagat cttagccact 2220
ttttaaaaga aaagggggga ctggaagggc taattcactc ccaacgaaga caagatatcc 2280
ttgatctgtg gatctaccac acacaaggct acttccctga ttggcagaac tacacaccag 2340
ggccagggat cagatatcca ctgacctttg gatggtgcta caagctagta ccagttgagc 2400
aagagaaggt agaagaagcc aatgaaggag agaacacccg cttgttacac cctgtgagcc 2460
tgcatgggat ggatgacccg gagagagaag tattagagtg gaggtttgac agccgcctag 2520
catttcatca catggcccga gagctgcatc cggactgtac tgggtctctc tggttagacc 2580
agatctgagc ctgggagctc tctggctaac tagggaaccc actgcttaag cctcaataaa 2640
gcttgccttg agtgcttcaa gtagtgtgtg cccgtctgtt gtgtgactct ggtaactaga 2700
gatccctcag acccttttag tcagtgtgga aaatctctag cagcatgtga gcaaaaggcc 2760
agcaaaaggc caggaaccgt aaaaaggccg cgttgctggc gtttttccat aggctccgcc 2820
cccctgacga gcatcacaaa aatcgacgct caagtcagag gtggcgaaac ccgacaggac 2880
tataaagata ccaggcgttt ccccctggaa gctccctcgt gcgctctcct gttccgaccc 2940
tgccgcttac cggatacctg tccgcctttc tcccttcggg aagcgtggcg ctttctcata 3000
gctcacgctg taggtatctc agttcggtgt aggtcgttcg ctccaagctg ggctgtgtgc 3060
acgaaccccc cgttcagccc gaccgctgcg ccttatccgg taactatcgt cttgagtcca 3120
acccggtaag acacgactta tcgccactgg cagcagccac tggtaacagg attagcagag 3180
cgaggtatgt aggcggtgct acagagttct tgaagtggtg gcctaactac ggctacacta 3240
gaagaacagt atttggtatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg 3300
gtagctcttg atccggcaaa caaaccaccg ctggtagcgg tggttttttt gtttgcaagc 3360
agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggt 3420
ctgacgctca gtggaacgaa aactcacgtt aagggatttt ggtcatgaga ttatcaaaaa 3480
ggatcttcac ctagatcctt ttaaattaaa aatgaagttt taaatcaatc taaagtatat 3540
atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga 3600
tctgtctatt tcgttcatcc atagttgcct gactccccgt cgtgtagata actacgatac 3660
gggagggctt accatctggc cccagtgctg caatgatacc gcgagaccca cgctcaccgg 3720
ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgcaga agtggtcctg 3780
caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtagtt 3840
cgccagttaa tagtttgcgc aacgttgttg ccattgctac aggcatcgtg gtgtcacgct 3900
cgtcgtttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga gttacatgat 3960
cccccatgtt gtgcaaaaaa gcggttagct ccttcggtcc tccgatcgtt gtcagaagta 4020
agttggccgc agtgttatca ctcatggtta tggcagcact gcataattct cttactgtca 4080
tgccatccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca ttctgagaat 4140
agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat acgggataat accgcgccac 4200
atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga aaactctcaa 4260
ggatcttacc gctgttgaga tccagttcga tgtaacccac tcgtgcaccc aactgatctt 4320
cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg 4380
caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc ctttttcaat 4440
attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt gaatgtattt 4500
agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcca cctgacgtcg 4560
acggatcggg agatctcccg atcccctatg gtgcactctc agtacaatct gctctgatgc 4620
cgcatagtta agccagtatc tgctccctgc ttgtgtgttg gaggtcgctg agtagtgcgc 4680
gagcaaaatt taagctacaa caaggcaagg cttgaccgac aattgcatga agaatctgct 4740
tagggttagg cgttttgcgc tgcttcgcga tgtacgggcc agatatacgc gttgacattg 4800
attattgact agttattaat agtaatcaat tacggggtca ttagttcata gcccatatat 4860
ggagttccgc gttacataac ttacggtaaa tggcccgcct ggctgaccgc ccaacgaccc 4920
ccgcccattg acgtcaataa tgacgtatgt tcccatagta acgccaatag ggactttcca 4980
ttgacgtcaa tgggtggagt atttacggta aactgcccac ttggcagtac atcaagtgta 5040
tcatatgcca agtacgcccc ctattgacgt caatgacggt aaatggcccg cctggcatta 5100
tgcccagtac atgaccttat gggactttcc tacttggcag tacatctacg tattagtcat 5160
cgctattacc atggtgatgc ggttttggca gtacatcaat gggcgtggat agcggtttga 5220
ctcacgggga tttccaagtc tccaccccat tgacgtcaat gggagtttgt tttggcacca 5280
aaatcaacgg gactttccaa aatgtcgtaa caactccgcc ccattgacgc aaatgggcgg 5340
taggcgtgta cggtgggagg tctatataag cagcgcgttt tgcctgtact gggtctctct 5400
ggttagacca gatctgagcc tgggagctct ctggctaact agggaaccca ctgcttaagc 5460
ctcaataaag cttgccttga gtgcttcaag tagtgtgtgc ccgtctgttg tgtgactctg 5520
gtaactagag atccctcaga cccttttagt cagtgtggaa aatctctagc agtggcgccc 5580
gaacagggac ttgaaagcga aagggaaacc agaggagctc tctcgacgca ggactcggct 5640
tgctgaagcg cgcacggcaa gaggcgaggg gcggcgactg gtgagtacgc caaaaatttt 5700
gactagcgga ggctagaagg agagagatgg gtgcgagagc gtcagtatta agcgggggag 5760
aattagatcg cgatgggaaa aaattcggtt aaggccaggg ggaaagaaaa aatataaatt 5820
aaaacatata gtatgggcaa gcagggagct agaacgattc gcagttaatc ctggcctgtt 5880
agaaacatca gaaggctgta gacaaatact gggacagcta caaccatccc ttcagacagg 5940
atcagaagaa cttagatcat tatataatac agtagcaacc ctctattgtg tgcatcaaag 6000
gatagagata aaagacacca aggaagcttt agacaagata gaggaagagc aaaacaaaag 6060
taagaccacc gcacagcaag cggccggccg ctgatcttca gacctggagg aggagatatg 6120
agggacaatt ggagaagtga attatataaa tataaagtag taaaaattga accattagga 6180
gtagcaccca ccaaggcaaa gagaagagtg gtgcagagag aaaaaagagc agtgggaata 6240
ggagctttgt tccttgggtt cttgggagca gcaggaagca ctatgggcgc agcgtcaatg 6300
acgctgacgg tacaggccag acaattattg tctggtatag tgcagcagca gaacaatttg 6360
ctgagggcta ttgaggcgca acagcatctg ttgcaactca cagtctgggg catcaagcag 6420
ctccaggcaa gaatcctggc tgtggaaaga tacctaaagg atcaacagct cctggggatt 6480
tggggttgct ctggaaaact catttgcacc actgctgtgc cttggaatgc tagttggagt 6540
aataaatctc tggaacagat ttggaatcac acgacctgga tggagtggga cagagaaatt 6600
aacaattaca caagcttaat acactcctta attgaagaat cgcaaaacca gcaagaaaag 6660
aatgaacaag aattattgga attagataaa tgggcaagtt tgtggaattg gtttaacata 6720
acaaattggc tgtggtatat aaaattattc ataatgatag taggaggctt ggtaggttta 6780
agaatagttt ttgctgtact ttctatagtg aatagagtta ggcagggata ttcaccatta 6840
tcgtttcaga cccacctccc aaccccgagg ggacccgaca ggcccgaagg aatagaagaa 6900
gaaggtggag agagagacag agacagatcc attcgattag tgaacggatc ggcactgcgt 6960
gcgccaattc tgcagacaaa tggcagtatt catccacaat tttaaaagaa aaggggggat 7020
tggggggtac agtgcagggg aaagaatagt agacataata gcaacagaca tacaaactaa 7080
agaattacaa aaacaaatta caaaaattca aaattttcgg gtttattaca gggacagcag 7140
agatccagtt tggttagtac cgggcccgct ctagagatcc gacgcgccat ctctaggccc 7200
gcgccggccc cctcgcacag acttgtggga gaagctcggc tactcccctg ccccggttaa 7260
tttgcatata atatttccta gtaactatag aggcttaatg tgcgataaaa gacagataat 7320
ctgttctttt taatactagc tacattttac atgataggct tggatttcta taagagatac 7380
aaatactaaa ttattatttt aaaaaacagc acaaaaggaa actcacccta actgtaaagt 7440
aattgtgtgt tttgagacta taaatatccc ttggagaaaa gccttgttaa cgcgcggtga 7500
ccctcgaggt cgacggtatc gataagctcg cttcacgaga ttccagcagg tcgagggacc 7560
taataacttc gtatagcata cattatacga agttatatta agggttccaa gcttaagcgg 7620
ccgcgtggat aaccgtatta ccgccat 7647
<210> 2
<211> 1646
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
tctagacagt agtcgccgtg aacgttcttt ttcgcaacgg gtttgccgcc agaacacagc 60
tgaagcttcg aggggctcgc atctctcctt cacgcgcccg ccgccctacc tgaggccgcc 120
atccacgccg gttgagtcgc gttctgccgc ctcccgcctg tggtgcctcc tgaactgcgt 180
ccgccgtcta ggtaagttta aagctcaggt cgagaccggg cctttgtccg gcgctccctt 240
ggagcctacc tagactcagc cggctctcca cgctttgcct gaccctgctt gctcaactct 300
acgtctttgt ttcgttttct gttctgcgcc gttacagatc caagctgtga ccggggttta 360
gtgaaccgtc agatccgcca ccgctagcgc taatgtacaa gacgcgtcgc gtttcgaacc 420
cgggcccgga tcctgcgaat tctgcctaga taattctacc gggtagggga ggcgcttttc 480
ccaaggcagt ctggagcatg cgctttagca gccccgctgg gcacttggcg ctacacaagt 540
ggcctctggc ctcgcacaca ttccacatcc accggtaggc gccaaccggc tccgttcttt 600
ggtggcccct tcgcgccacc ttctactcct cccctagtca ggaagttccc ccccgccccg 660
cagctcgcgt cgtgcaggac gtgacaaatg gaagtagcac gtctcactag tctcgtgcag 720
atggacagca ccgctgagca atggaagcgg gtaggccttt ggggcagcgg ccaatagcag 780
ctttgctcct tcgctttctg ggctcagagg ctgggaaggg gtgggtccgg gggcgggctc 840
aggggcgggc tcaggggcgg ggcgggcgcc cgaaggtcct ccggaggccc ggcattctgc 900
acgcttcaaa agcgcacgtc tgccgcgctg ttctcctctt cctcatctcc gggcctttcg 960
acatggcctc ctccgaggac gtcatcaagg agttcatgcg cttcaaggtg cgcatggagg 1020
gctccgtgaa cggccacgag ttcgagatcg agggcgaggg cgagggccgc ccctacgagg 1080
gcacccagac cgccaagctg aaggtgacca agggcggccc cctgcccttc gcctgggaca 1140
tcctgtcccc tcagttccag tacggctcca aggcctacgt gaagcacccc gccgacatcc 1200
ccgactactt gaagctgtcc ttccccgagg gcttcaagtg ggagcgcgtg atgaacttcg 1260
aggacggcgg cgtggtgacc gtgacccagg actcctccct gcaggacggc gagttcatct 1320
acaaggtgaa gctgcgcggc accaacttcc cctccgacgg ccccgtaatg cagaagaaga 1380
ccatgggctg ggaggcctcc accgagcgga tgtaccccga ggacggcgcc ctgaagggcg 1440
agatcaagat gaggctgaag ctgaaggacg gcggccacta cgacgccgag gtcaagacca 1500
cctacatggc caagaagccc gtgcagctgc ccggcgccta caagaccgac atcaagctgg 1560
acatcacctc ccacaacgag gactacacca tcgtggaaca gtacgagcgc gccgagggcc 1620
gccactccac cggcgcctaa acatgt 1646
<210> 3
<211> 7420
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
ttaagggttc cggttccact aggtacaatt cgatatcaag cttatcgata atcaacctct 60
ggattacaaa atttgtgaaa gattgactgg tattcttaac tatgttgctc cttttacgct 120
atgtggatac gctgctttaa tgcctttgta tcatgctatt gcttcccgta tggctttcat 180
tttctcctcc ttgtataaat cctggttgct gtctctttat gaggagttgt ggcccgttgt 240
caggcaacgt ggcgtggtgt gcactgtgtt tgctgacgca acccccactg gttggggcat 300
tgccaccacc tgtcagctcc tttccgggac tttcgctttc cccctcccta ttgccacggc 360
ggaactcatc gccgcctgcc ttgcccgctg ctggacaggg gctcggctgt tgggcactga 420
caattccgtg gtgttgtcgg ggaaatcatc gtcctttcct tggctgctcg cctgtgttgc 480
cacctggatt ctgcgcggga cgtccttctg ctacgtccct tcggccctca atccagcgga 540
ccttccttcc cgcggcctgc tgccggctct gcggcctctt ccgcgtcttc gccttcgccc 600
tcagacgagt cggatctccc tttgggccgc ctccccgcat cgataccgtc gacctcgatc 660
gagacctaga aaaacatgga gcaatcacaa gtagcaatac agcagctacc aatgctgatt 720
gtgcctggct agaagcacaa gaggaggagg aggtgggttt tccagtcaca cctcaggtac 780
ctttaagacc aatgacttac aaggcagctg tagatcttag ccacttttta aaagaaaagg 840
ggggactgga agggctaatt cactcccaac gaagacaaga tatccttgat ctgtggatct 900
accacacaca aggctacttc cctgattggc agaactacac accagggcca gggatcagat 960
atccactgac ctttggatgg tgctacaagc tagtaccagt tgagcaagag aaggtagaag 1020
aagccaatga aggagagaac acccgcttgt tacaccctgt gagcctgcat gggatggatg 1080
acccggagag agaagtatta gagtggaggt ttgacagccg cctagcattt catcacatgg 1140
cccgagagct gcatccggac tgtactgggt ctctctggtt agaccagatc tgagcctggg 1200
agctctctgg ctaactaggg aacccactgc ttaagcctca ataaagcttg ccttgagtgc 1260
ttcaagtagt gtgtgcccgt ctgttgtgtg actctggtaa ctagagatcc ctcagaccct 1320
tttagtcagt gtggaaaatc tctagcagca tgtgagcaaa aggccagcaa aaggccagga 1380
accgtaaaaa ggccgcgttg ctggcgtttt tccataggct ccgcccccct gacgagcatc 1440
acaaaaatcg acgctcaagt cagaggtggc gaaacccgac aggactataa agataccagg 1500
cgtttccccc tggaagctcc ctcgtgcgct ctcctgttcc gaccctgccg cttaccggat 1560
acctgtccgc ctttctccct tcgggaagcg tggcgctttc tcatagctca cgctgtaggt 1620
atctcagttc ggtgtaggtc gttcgctcca agctgggctg tgtgcacgaa ccccccgttc 1680
agcccgaccg ctgcgcctta tccggtaact atcgtcttga gtccaacccg gtaagacacg 1740
acttatcgcc actggcagca gccactggta acaggattag cagagcgagg tatgtaggcg 1800
gtgctacaga gttcttgaag tggtggccta actacggcta cactagaaga acagtatttg 1860
gtatctgcgc tctgctgaag ccagttacct tcggaaaaag agttggtagc tcttgatccg 1920
gcaaacaaac caccgctggt agcggtggtt tttttgtttg caagcagcag attacgcgca 1980
gaaaaaaagg atctcaagaa gatcctttga tcttttctac ggggtctgac gctcagtgga 2040
acgaaaactc acgttaaggg attttggtca tgagattatc aaaaaggatc ttcacctaga 2100
tccttttaaa ttaaaaatga agttttaaat caatctaaag tatatatgag taaacttggt 2160
ctgacagtta ccaatgctta atcagtgagg cacctatctc agcgatctgt ctatttcgtt 2220
catccatagt tgcctgactc cccgtcgtgt agataactac gatacgggag ggcttaccat 2280
ctggccccag tgctgcaatg ataccgcgag acccacgctc accggctcca gatttatcag 2340
caataaacca gccagccgga agggccgagc gcagaagtgg tcctgcaact ttatccgcct 2400
ccatccagtc tattaattgt tgccgggaag ctagagtaag tagttcgcca gttaatagtt 2460
tgcgcaacgt tgttgccatt gctacaggca tcgtggtgtc acgctcgtcg tttggtatgg 2520
cttcattcag ctccggttcc caacgatcaa ggcgagttac atgatccccc atgttgtgca 2580
aaaaagcggt tagctccttc ggtcctccga tcgttgtcag aagtaagttg gccgcagtgt 2640
tatcactcat ggttatggca gcactgcata attctcttac tgtcatgcca tccgtaagat 2700
gcttttctgt gactggtgag tactcaacca agtcattctg agaatagtgt atgcggcgac 2760
cgagttgctc ttgcccggcg tcaatacggg ataataccgc gccacatagc agaactttaa 2820
aagtgctcat cattggaaaa cgttcttcgg ggcgaaaact ctcaaggatc ttaccgctgt 2880
tgagatccag ttcgatgtaa cccactcgtg cacccaactg atcttcagca tcttttactt 2940
tcaccagcgt ttctgggtga gcaaaaacag gaaggcaaaa tgccgcaaaa aagggaataa 3000
gggcgacacg gaaatgttga atactcatac tcttcctttt tcaatattat tgaagcattt 3060
atcagggtta ttgtctcatg agcggataca tatttgaatg tatttagaaa aataaacaaa 3120
taggggttcc gcgcacattt ccccgaaaag tgccacctga cgtcgacgga tcgggagatc 3180
tcccgatccc ctatggtgca ctctcagtac aatctgctct gatgccgcat agttaagcca 3240
gtatctgctc cctgcttgtg tgttggaggt cgctgagtag tgcgcgagca aaatttaagc 3300
tacaacaagg caaggcttga ccgacaattg catgaagaat ctgcttaggg ttaggcgttt 3360
tgcgctgctt cgcgatgtac gggccagata tacgcgttga cattgattat tgactagtta 3420
ttaatagtaa tcaattacgg ggtcattagt tcatagccca tatatggagt tccgcgttac 3480
ataacttacg gtaaatggcc cgcctggctg accgcccaac gacccccgcc cattgacgtc 3540
aataatgacg tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt 3600
ggagtattta cggtaaactg cccacttggc agtacatcaa gtgtatcata tgccaagtac 3660
gccccctatt gacgtcaatg acggtaaatg gcccgcctgg cattatgccc agtacatgac 3720
cttatgggac tttcctactt ggcagtacat ctacgtatta gtcatcgcta ttaccatggt 3780
gatgcggttt tggcagtaca tcaatgggcg tggatagcgg tttgactcac ggggatttcc 3840
aagtctccac cccattgacg tcaatgggag tttgttttgg caccaaaatc aacgggactt 3900
tccaaaatgt cgtaacaact ccgccccatt gacgcaaatg ggcggtaggc gtgtacggtg 3960
ggaggtctat ataagcagcg cgttttgcct gtactgggtc tctctggtta gaccagatct 4020
gagcctggga gctctctggc taactaggga acccactgct taagcctcaa taaagcttgc 4080
cttgagtgct tcaagtagtg tgtgcccgtc tgttgtgtga ctctggtaac tagagatccc 4140
tcagaccctt ttagtcagtg tggaaaatct ctagcagtgg cgcccgaaca gggacttgaa 4200
agcgaaaggg aaaccagagg agctctctcg acgcaggact cggcttgctg aagcgcgcac 4260
ggcaagaggc gaggggcggc gactggtgag tacgccaaaa attttgacta gcggaggcta 4320
gaaggagaga gatgggtgcg agagcgtcag tattaagcgg gggagaatta gatcgcgatg 4380
ggaaaaaatt cggttaaggc cagggggaaa gaaaaaatat aaattaaaac atatagtatg 4440
ggcaagcagg gagctagaac gattcgcagt taatcctggc ctgttagaaa catcagaagg 4500
ctgtagacaa atactgggac agctacaacc atcccttcag acaggatcag aagaacttag 4560
atcattatat aatacagtag caaccctcta ttgtgtgcat caaaggatag agataaaaga 4620
caccaaggaa gctttagaca agatagagga agagcaaaac aaaagtaaga ccaccgcaca 4680
gcaagcggcc ggccgctgat cttcagacct ggaggaggag atatgaggga caattggaga 4740
agtgaattat ataaatataa agtagtaaaa attgaaccat taggagtagc acccaccaag 4800
gcaaagagaa gagtggtgca gagagaaaaa agagcagtgg gaataggagc tttgttcctt 4860
gggttcttgg gagcagcagg aagcactatg ggcgcagcgt caatgacgct gacggtacag 4920
gccagacaat tattgtctgg tatagtgcag cagcagaaca atttgctgag ggctattgag 4980
gcgcaacagc atctgttgca actcacagtc tggggcatca agcagctcca ggcaagaatc 5040
ctggctgtgg aaagatacct aaaggatcaa cagctcctgg ggatttgggg ttgctctgga 5100
aaactcattt gcaccactgc tgtgccttgg aatgctagtt ggagtaataa atctctggaa 5160
cagatttgga atcacacgac ctggatggag tgggacagag aaattaacaa ttacacaagc 5220
ttaatacact ccttaattga agaatcgcaa aaccagcaag aaaagaatga acaagaatta 5280
ttggaattag ataaatgggc aagtttgtgg aattggttta acataacaaa ttggctgtgg 5340
tatataaaat tattcataat gatagtagga ggcttggtag gtttaagaat agtttttgct 5400
gtactttcta tagtgaatag agttaggcag ggatattcac cattatcgtt tcagacccac 5460
ctcccaaccc cgaggggacc cgacaggccc gaaggaatag aagaagaagg tggagagaga 5520
gacagagaca gatccattcg attagtgaac ggatcggcac tgcgtgcgcc aattctgcag 5580
acaaatggca gtattcatcc acaattttaa aagaaaaggg gggattgggg ggtacagtgc 5640
aggggaaaga atagtagaca taatagcaac agacatacaa actaaagaat tacaaaaaca 5700
aattacaaaa attcaaaatt ttcgggttta ttacagggac agcagagatc cagtttggtt 5760
agtaccgggc ccgctctaga cagtagtcgc cgtgaacgtt ctttttcgca acgggtttgc 5820
cgccagaaca cagctgaagc ttcgaggggc tcgcatctct ccttcacgcg cccgccgccc 5880
tacctgaggc cgccatccac gccggttgag tcgcgttctg ccgcctcccg cctgtggtgc 5940
ctcctgaact gcgtccgccg tctaggtaag tttaaagctc aggtcgagac cgggcctttg 6000
tccggcgctc ccttggagcc tacctagact cagccggctc tccacgcttt gcctgaccct 6060
gcttgctcaa ctctacgtct ttgtttcgtt ttctgttctg cgccgttaca gatccaagct 6120
gtgaccgggg tttagtgaac cgtcagatcc gccaccgcta gcgctaatgt acaagacgcg 6180
tcgcgtttcg aacccgggcc cggatcctgc gaattctgcc tagataattc taccgggtag 6240
gggaggcgct tttcccaagg cagtctggag catgcgcttt agcagccccg ctgggcactt 6300
ggcgctacac aagtggcctc tggcctcgca cacattccac atccaccggt aggcgccaac 6360
cggctccgtt ctttggtggc cccttcgcgc caccttctac tcctccccta gtcaggaagt 6420
tcccccccgc cccgcagctc gcgtcgtgca ggacgtgaca aatggaagta gcacgtctca 6480
ctagtctcgt gcagatggac agcaccgctg agcaatggaa gcgggtaggc ctttggggca 6540
gcggccaata gcagctttgc tccttcgctt tctgggctca gaggctggga aggggtgggt 6600
ccgggggcgg gctcaggggc gggctcaggg gcggggcggg cgcccgaagg tcctccggag 6660
gcccggcatt ctgcacgctt caaaagcgca cgtctgccgc gctgttctcc tcttcctcat 6720
ctccgggcct ttcgacatgg cctcctccga ggacgtcatc aaggagttca tgcgcttcaa 6780
ggtgcgcatg gagggctccg tgaacggcca cgagttcgag atcgagggcg agggcgaggg 6840
ccgcccctac gagggcaccc agaccgccaa gctgaaggtg accaagggcg gccccctgcc 6900
cttcgcctgg gacatcctgt cccctcagtt ccagtacggc tccaaggcct acgtgaagca 6960
ccccgccgac atccccgact acttgaagct gtccttcccc gagggcttca agtgggagcg 7020
cgtgatgaac ttcgaggacg gcggcgtggt gaccgtgacc caggactcct ccctgcagga 7080
cggcgagttc atctacaagg tgaagctgcg cggcaccaac ttcccctccg acggccccgt 7140
aatgcagaag aagaccatgg gctgggaggc ctccaccgag cggatgtacc ccgaggacgg 7200
cgccctgaag ggcgagatca agatgaggct gaagctgaag gacggcggcc actacgacgc 7260
cgaggtcaag accacctaca tggccaagaa gcccgtgcag ctgcccggcg cctacaagac 7320
cgacatcaag ctggacatca cctcccacaa cgaggactac accatcgtgg aacagtacga 7380
gcgcgccgag ggccgccact ccaccggcgc ctaaacatgt 7420
<210> 4
<211> 555
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
ggatccgcca ccatgcacag ctcagcactg ctctgttgcc tggtcctcct gactggggtg 60
agggccagcc caggccaggg cacccagtct gagaacagct gcacccactt cccaggcaac 120
ctgcctaaca tgcttcgaga tctccgagat gccttcagca gagtgaagac tttctttcaa 180
atgaaggatc agctggacaa cttgttgtta aaggagtcct tgctggagga ctttaagggt 240
tacctgggtt gccaagcctt gtctgagatg atccagtttt acctggagga ggtgatgccc 300
caagctgaga accaagaccc agacatcaag gcgcatgtga actccctggg ggagaacctg 360
aagaccctca ggctgaggct acggcgctgt catcgatttc ttccctgtga aaacaagagc 420
aaggccgtgg agcaggtgaa gaatgccttt aataagctcc aagagaaagg catctacaaa 480
gccatgagtg agtttgacat cttcatcaac tacatagaag cctacatgac aatgaagata 540
cgaaactgag aattc 555
Claims (6)
1. The nucleotide sequence of the lentiviral vector for the stem cell gene modification is shown as SEQ ID NO. 2.
2. Use of the lentiviral vector of claim 1 for genetic modification of a stem cell.
3. The method of constructing a lentiviral vector according to claim 1, comprising the steps of: selecting a single enzyme cutting site XbaI and a single enzyme cutting site Pci I to cut a CMV + EGHFP element on the initial vector, wherein the size of the vector after enzyme cutting is 5780bp, the synthesized EF1a-MCS-PGK-RFP sequence is added with the sequence of XbaI or Pci I at two ends respectively.
4. Use of the lentiviral vector of claim 1, comprising the steps of:
step 1: cloning a target gene into a vector to obtain a recombinant lentivirus vector;
step 2: co-transfecting the recombinant lentiviral vector with psPAX2 and pMD2.0G to a host cell;
and step 3: culturing host cells
And 4, step 4: and separating to obtain the recombinant lentivirus.
5. A recombinant lentiviral vector is prepared by the following method: cloning of neutralizing antibody sequences of immunomodulatory cytokine genes or anti-inflammatory cytokines into the polyclonal site of the lentiviral vector for stem cell genetic modification of claim 1.
6. The recombinant lentiviral vector of claim 5, wherein the immunomodulatory cytokine gene is selected from any one or more of human TGF- β, IL-10, or IL-4; the neutralizing anti-inflammatory cytokine antibody includes any one or more of anti-human IL-6, TNF-a or IL-1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210342741.2A CN114990163A (en) | 2022-03-31 | 2022-03-31 | Lentiviral vector for stem cell gene modification and construction method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210342741.2A CN114990163A (en) | 2022-03-31 | 2022-03-31 | Lentiviral vector for stem cell gene modification and construction method and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114990163A true CN114990163A (en) | 2022-09-02 |
Family
ID=83023560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210342741.2A Pending CN114990163A (en) | 2022-03-31 | 2022-03-31 | Lentiviral vector for stem cell gene modification and construction method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114990163A (en) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101361984A (en) * | 2008-09-12 | 2009-02-11 | 清华大学 | Use of Dpys 12 gene in preparing medicine for inhibiting or promoting early neurogenesis |
CN101397573A (en) * | 2007-09-25 | 2009-04-01 | 首都医科大学宣武医院 | Lentiviral vectors expressing glial derived neurotrophic factor and uses thereof |
CN101555487A (en) * | 2008-04-09 | 2009-10-14 | 广东药学院 | RNA interference carrier used for osteoporosis and rat mesenchymal stem cells |
CN104059943A (en) * | 2014-07-04 | 2014-09-24 | 武汉大学 | Panx3 gene overexpression red fluorescence lentiviral vector and building method and application thereof |
JP2015223143A (en) * | 2014-05-29 | 2015-12-14 | 国立大学法人富山大学 | Nk cell strain for evaluating cytotoxic activity-inducing potency of tcr, and production method thereof |
KR20190000569A (en) * | 2017-06-23 | 2019-01-03 | 주식회사 녹십자랩셀 | Transformed stem cell expressing glb1 gene and pharmaceutical composition for treating gm1 gangliosidosis comprising same |
CN109913499A (en) * | 2017-12-13 | 2019-06-21 | 上海吉凯基因化学技术有限公司 | It is a kind of suitable for long-chain non-coding RNA construct and express integrated slow virus carrier system and its application |
US20190233797A1 (en) * | 2016-09-29 | 2019-08-01 | Nantkwest, Inc. | Hla class i-deficient nk-92 cells with decreased immunogenicity |
US20210316013A1 (en) * | 2018-12-23 | 2021-10-14 | Csl Behring Llc | Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome |
-
2022
- 2022-03-31 CN CN202210342741.2A patent/CN114990163A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101397573A (en) * | 2007-09-25 | 2009-04-01 | 首都医科大学宣武医院 | Lentiviral vectors expressing glial derived neurotrophic factor and uses thereof |
CN101555487A (en) * | 2008-04-09 | 2009-10-14 | 广东药学院 | RNA interference carrier used for osteoporosis and rat mesenchymal stem cells |
CN101361984A (en) * | 2008-09-12 | 2009-02-11 | 清华大学 | Use of Dpys 12 gene in preparing medicine for inhibiting or promoting early neurogenesis |
JP2015223143A (en) * | 2014-05-29 | 2015-12-14 | 国立大学法人富山大学 | Nk cell strain for evaluating cytotoxic activity-inducing potency of tcr, and production method thereof |
CN104059943A (en) * | 2014-07-04 | 2014-09-24 | 武汉大学 | Panx3 gene overexpression red fluorescence lentiviral vector and building method and application thereof |
US20190233797A1 (en) * | 2016-09-29 | 2019-08-01 | Nantkwest, Inc. | Hla class i-deficient nk-92 cells with decreased immunogenicity |
KR20190000569A (en) * | 2017-06-23 | 2019-01-03 | 주식회사 녹십자랩셀 | Transformed stem cell expressing glb1 gene and pharmaceutical composition for treating gm1 gangliosidosis comprising same |
CN109913499A (en) * | 2017-12-13 | 2019-06-21 | 上海吉凯基因化学技术有限公司 | It is a kind of suitable for long-chain non-coding RNA construct and express integrated slow virus carrier system and its application |
US20210316013A1 (en) * | 2018-12-23 | 2021-10-14 | Csl Behring Llc | Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome |
Non-Patent Citations (1)
Title |
---|
刘超等: "Mmu-miR-34c 慢病毒表达载体构建及在奶山羊雄性生殖干细胞的表达", 中国农业科学, 31 December 2012 (2012-12-31) * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021200988B2 (en) | Gene therapy for retinitis pigmentosa | |
CN111372943B (en) | Adenovirus and use thereof | |
DK2753355T3 (en) | ONCOLYTIC HERP SIMPLEX VIRUSES AND THERAPEUTIC APPLICATIONS THEREOF | |
US20040214290A1 (en) | Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes | |
CN101208425A (en) | Cell lines for production of replication-defective adenovirus | |
US6187991B1 (en) | Transgenic animal models for type II diabetes mellitus | |
CN108949825A (en) | A kind of preparation method and application for the CAR-T cell targeting HER2 | |
KR20220163950A (en) | Double bifunctional vectors for AAV production | |
KR101616572B1 (en) | Combined measles-malaria vaccine | |
CN110582305A (en) | Vectors and compositions for the treatment of hemoglobinopathies | |
WO1992017581A1 (en) | Mammalian expression vector | |
CN114032217A (en) | Novel coronavirus compound vaccine based on DNA vector and replicative vaccinia virus vector | |
CN110305902B (en) | Method for activating hSyn promoter in tool cell and application thereof | |
CN114990163A (en) | Lentiviral vector for stem cell gene modification and construction method and application thereof | |
SK10696A3 (en) | Extraction method of periplasmatic proteins from prokaryotic microorganisms | |
CN115707779B (en) | Recombinant coxsackievirus A16 virus-like particles and uses thereof | |
KR20220064647A (en) | Synthetic Promoter Based Gene from Acid Resistant Yeast | |
CN101679976A (en) | nucleic acids and libraries | |
CN113846071B (en) | Alanine-glyoxylate transaminase mutant with improved enzyme activity and application thereof | |
CN111492059A (en) | Methods for genome editing in host cells | |
KR20220150323A (en) | Fully Synthetic Long-Chain Nucleic Acids for Production of Vaccines Against Coronavirus | |
CN114250239A (en) | Construction method and application of glycine riboswitch gene regulation circuit | |
KR20230153437A (en) | Fully synthetic long-chain nucleic acid for producing vaccines against coronavirus | |
KR20150045872A (en) | Foot-and-mouth disease vaccine strain using Porcine Reproductive and Respiraritory Syndrome virus replicon | |
NZ553497A (en) | Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |